{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"OS is defined as the time from the date of first dose of study treatment until death by any cause or the last date the patient was known to be alive.","groups":[{"description":"Patients will receive INCMGA00012 500 mg by intravenous infusion on Day1 of each cycle.\n\nRetifanlimab: INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.","id":"OG000","title":"Interventional Arm"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From baseline until disease progression or treatment discontinuation, up to 10.3 months","title":"Efficacy Determined by Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Participants"}